|

|
 |
 |
 |
|
![]() |
 |
BSD Medical Corporation (NASDAQ:BSDM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy as provided by focused radio frequency and microwave energy. BSD Medical is also making major progress in the application of its technology for other therapies.
Microwave hyperthermia therapy has been shown to substantially improve local control of cancer, tumor response and survival rates when added to radiation treatments. In phase III clinical trials where hyperthermia was combined with radiation therapy, hyperthermia improved 2-year local control of melanoma from 28% to 46%, complete response for recurrent breast cancer from 38% to 60%, 2-year survival for glioblastoma (brain cancer) from 15% to 31% and complete response for advanced cervical cancer from 57% to 83%, as compared to the use of radiation therapy alone.
BSD Medical Corporation was the first company to obtain PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for a hyperthermia cancer therapy system and the first company to obtain Investigational Device Exemption (IDE) approval from the FDA for thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH). BSD has sold and manufactured over 200 hyperthermia systems installed throughout the world. Since its founding, BSD Medical has invested over $20 million in development of technology for hyperthermia treatment, and substantially greater funding has been provided for the clinical trials by the U.S. National Institutes of Health (NIH) and European governments.
BSD is also the developer of the microwave thermal therapy systems used by TherMatrx, Inc., a company dedicated to the treatment of symptoms associated with enlarged prostate, a health condition affecting half of men over age 50. BSD Medical is currently engaged in an earn-out that is projected to provide a cash return of approximately $30-40 million for the sales of its shares in TherMatrx, Inc.
BSD Medical has 9 U.S. patents, 3 foreign patents and 5 patent licenses covering its current applications and products. New technologies are also under development that may qualify for patent protection.
Four additional BSD patents that apply to the treatment of enlarged prostate (BPH), a urological disease, have been assigned to TherMatrx, Inc. BSD Medical’s prior licensee, Urologix, Inc. (NAS :ULGX), which has marketed under license to these patents, subsequently became a licensee to TherMatrx.
Over 1,000 researchers, consisting substantially of physicians and physicists, are members of world organizations dedicated exclusively to research in hyperthermic oncology. Three hyperthermia research organizations service North America, Europe and Asia.
In the opening address of the 2001 annual conference of the North American Hyperthermic Society (sponsored by the Radiological Society of North America), P. K. Sneed, M. D. (Univ. of California San Francisco) offered the following summary of completed Phase III randomized clinical trials involving combination ionizing radiation (RT) plus hyperthermia therapy (HT) vs. ionizing radiation treatments alone: “for melanoma (2-year local control 28% for RT vs. 46% for RT + HT), recurrent breast cancer (complete response rate 38% for RT vs. 60% for RT + HT), glioblastoma (2-year survival 15% for RT vs. 31% for RT + HT), and advanced cervical cancer (complete response rate 57% for RT vs. 83% for RT + HT).”
BSD Medical Corporation has developed the technology required to approach hyperthermia therapy through three techniques: superficial, interstitial and deep hyperthermia. These methods allow cancer to be treated virtually anywhere in the body.
Superficial hyperthermia systems are used to non-invasively treat tumors within a few centimeters of the surface of the body, typical in conditions of melanoma and recurrent breast cancer. Interstitial hyperthermia is primarily used to treat tumors in combination with popular interstitial and endocavitary ionizing radiation therapy (brachytherapy), using tiny microwave antennae inserted through the same catheters required to deliver radioactive seeds. This technique can be employed in treating prostate cancer, breast cancer, head and neck cancer and a variety of other cancer sites. Deep hyperthermia is used to non-invasively treat tumors deep within the body, including many problematic cancer sites located in the pelvis, abdomen and chest areas.
Development of the BSD-2000 has been a substantial effort involving the cooperative work of such American research institutions as Duke University, Northwestern University, University of Southern California, Stanford University, University of Utah and University of Washington St. Louis. Contributing
European research institutions included Daniel den Hoed Cancer Center of the Academisch Ziekenhuis (Rotterdam, Netherlands), Haukeland University Hospital (Bergen, Norway), Düsseldorf University Medical School, Tübingen University Medical School, Essen University Hospital, Charité Medical School of Humboldt University (Berlin), Luebeck University Medical School, Munich University Medical School Grosshadern, Interne Klinik Argirov of the Munich Comprehensive Cancer Center (all of Germany), University of Verona Medical Center (Italy), Graz University Medical School (Austria) and Kantonsspital Aarau (Switzerland).
Through research funded by the National Cancer Institute and supportive efforts by other research institutions, BSD Medical has been able to further enhance the BSD-2000. The BSD-2000/3D adds three-dimensional steering of deep focused energy, delivering even more precise heating to the tumor. As part of the international collaborative research efforts, sophisticated treatment planning software for the BSD-2000/3D has also been developed.
Both the BSD-2000 and BSD-2000/3D administer non-invasive treatment to deep tumors. As a further objective, MRI treatment monitoring has also been added. The BSD-2000/3D/MR provides magnetic resonance imaging (MRI) as an interface with the BSD-2000/3D. The development of MRI treatment monitoring has been a long-awaited breakthrough in hyperthermic oncology. Among many benefits, MRI treatment monitoring opens the way for the application of MRI monitored hyperthermia for better treatment of new cancer sites, using non-invasive imaging (including temperature monitoring) of tumors during therapy.
|
|
![]() |
 |
Click
on the date of the Financial Statement you wish
to view. Each date is directly linked to the EDGAR
Database located on the U.S.
Securities and Exchange Commission server.
- April 10, 2008 Form 8-K
- February 29, 2008 Form 10-QSB
- November 30, 2007 Form 10-QSB
- August 31, 2007 Form 10-KSB
- May 31, 2007 Form 10-QSB
- February 28, 2007 Form 10-QSB
- November 30, 2006 Form 10-QSB
- August 31, 2006 Form 10-KSB
- May 31, 2006 Form 10-QSB
- February 28, 2006 Form 10-QSB
- November 30, 2005 Form 10-KSB
- July 26, 2005 Form 8-K
- July 07, 2005 Form 8-K
- June 23, 2005 Form 8-K
- June 21, 2005 Form 8-K
- May 31, 2005 Form 10-QSB
- February 28, 2005 Form 10-QSB
- November 30, 2004 Form 10-QSB
- August 31, 2004 Form 10-KSB
- July 18, 2004 Form 8-K
- July 15, 2004 Form 8-K
- June 16, 2004 Form 8-K
- May 31, 2004 Form 10-QSB
- May 21, 2004 Form 8-K
- May 11, 2004 Form 8-K
- April 22, 2004 Form 8-K
- April 20, 2004 Form 8-K
- February 29, 2004 Form 10-QSB
- December 10, 2003 Form 8-K
- November 30, 2003 Form 8-K
- August 31, 2003 Form 10-KSB
- May 31, 2003 Form 10-QSB
|
- February 28, 2002 Form 10-QSB
- November 30, 2001 Form 10-QSB
- August 31, 2001 Form 10-KSQ
- May 31, 2001 Form 10-QSB
- February 28, 2001 Form 10-QSB
- November 30, 2000 Form 10-QSB
- August 31, 2000 Form 10-KSB
- July 01, 2000 Form 8-K
- May 31, 2000 Form 10-QSB
- February 29, 2000 Form 10-QSB
- November 30, 1999 Form 10-QSB
- August 31, 1999 Form 10-KSB
- May 31, 1999 Form 10-QSB
- April 13, 1999 Form 8-K
- February 28, 1999 Form 8-K
- November 30, 1998 Form 10-QSB
- August 31, 1998 Form 10-KSB
- May 31, 1998 Form 10-QSB
- May 26, 1998 Form 8-K
- February 28, 1998 Form 10-QSB
- December 22, 1997 Form 8-K
- November 30, 1997 Form 10-KSQ
- November 14, 1997 Form 8-K
- August 31, 1997 Form 10-KSB
- August 14, 1997 Form 8-K
- August 14, 1997 Form 8-K/A
- August 14, 1997 Form 8-K/A
- May 31, 1997 Form 10-QSB
- February 28, 1997 Form 10-QSB
- November 30, 1996 Form 10-QSB
- August 31, 1996 Form 10-KSB
|
| If
you would like copies of older Financial Statements
or have any specific questions, please send
your request to investor@bsdmc.com. |
|
|
![]() |
 |
BSD Medical has 46 employees who provide a broad complement of management, technical, regulatory, sales, marketing, production and administrative skills. Several key employees, including a seasoned medical sales director and a senior engineer have joined the BSD to complement the company’s growth plans. The Board of Directors and selected critical employees are as follows:
Paul F. Turner, MSEE (Chairman/Senior VP/Chief Technology Officer) joined BSD Medical Corporation in 1978 after seven years as a respected developer of microwave communications systems for Sperry Univac (now L3 Communications). His experience with advanced military defense communication systems prepared him to lead the development of sophisticated phased array microwave technology at BSD Medical. Mr. Turner has led the design of microwave treatment systems for tumors, including the development of external phased array antenna technology to focus radiated microwave energy deep into the central area of the body to treat deep tumors. He has also integrated this novel technology with Magnetic Resonance Imaging (MRI) to non-invasively monitor treatments within the patient's body. He is also a member of the STM Professional Affairs Committee
Hyrum A. Mead, MBA (President/CEO) joined BSD and elected to the Board of Directors in 1999. Previously he served five years as Vice President Business Development for ZERO Enclosures, a leading manufacturer in the telecommunications, computer and aerospace enclosures industry. He also served seven years as President of Electro Controls, a manufacturer of computer controlled power systems. Mr. Mead began his career in marketing with IBM where he worked with the introduction of many new products. His career has focused on growing businesses and making them successful, including turnarounds.
Dr. Gerhard Sennewald (Director) was appointed to BSD's Board of Directors in 1994. He has been a key BSD European representative and distributor. Dr. Sennewald is President and Chief Executive Officer of Medizin-Technik GmbH of Munich, Germany.
Dr. Michael Nobel (Director) was appointed to the Board of Directors in 1998. Dr. Nobel is Chairman of the Board of the Nobel Family Society that provides Nobel Prizes, including the Nobel Peace Prize. He is Chairman of the American Non-Violence Project Inc., and has served as a consultant to Unesco in Paris and the United Nations Social Affairs Division in Geneva. Dr. Nobel participated in the introduction of magnetic resonance imaging as European Vice President for Fonar Corp. He is the CEO of the MRAB Group which provides diagnostic imaging services.
Douglas P. Boyd, PhD (Director) Dr. Boyd founded Imatron in 1983, a medical technology company that produces electron beam tomography ("EBT") scanners, and served in various capacities, including Chairman and CEO. Imatron was later acquired by General Electric. Dr. Boyd also helped found Invision Technologies Inc., a company engaged in airport explosives detection. He served on the Invision board until its acquisition by General Electric in December 2004.
Dr. Boyd currently serves as Chairman of the Board of XLR Medical, Inc., as CEO of TeleSecurity Sciences, Inc., as Managing Director of Imaging Technology Ventures, Inc., and on the Board of Directors of Imaging Technology Group, Inc., TechniScan, Inc. and HealthAddress, Inc. He is internationally known as an expert in radiology and computed tomography ("CT") imaging systems, and has pioneered the development of fan-beam CT scanners, Xenon detector arrays and EBT scanners. Dr. Boyd has been awarded 13 U.S. patents. He is an Adjunct Professor of Radiology at the University of California, San Francisco, has published more than 100 scientific papers and is a frequent speaker at universities and symposiums.
Steven G. Stewart (Director) CPA, served as Chief Financial Officer for Headwaters, Inc. (a New York Exchange Company) from July 1998 until October 2005 when he became the Treasurer. Previously, Mr. Stewart served as a business assurance partner for PricewaterhouseCoopers LLP (formerly Coopers & Lybrand LLP), and as an audit partner with Ernst & Young (formerly Arthur Young), including service as the Director of High Technology and Entrepreneurial Services for the Salt Lake City office.
Timothy C. McQuay (Director) Mr. McQuay most recently served for ten years as Managing Director Investment Banking at A. G. Edwards & Sons, Inc. where he specialized in Healthcare, including medical technology, biotechnology and specialty pharmaceuticals. He previously served as Partner and Managing Director Investment Banking at Crowell, Weedon & Company; as Vice President Corporate Development at Kerr Group, Inc.; as Managing Director Merchant Banking at Union Bank of California; as Senior Vice-President Corporate Finance at Wedbush Morgan Securities, and as Vice-President Brokerage Services at Alexander & Alexander, Inc. Mr. McQuay holds an AB in Economics from Princeton University and an MBA from UCLA.
Dixie Toolson Sells (VP Regulatory Affairs) joined BSD Medical in 1978 and has directed the company’s regulatory affairs since 1984. Her efforts were largely instrumental in preparing the documentation required for obtaining FDA approval for the BSD-500 and for the products sold to TherMatrx, Inc. She currently leads the project to obtain FDA approval for the BSD-2000 and FDA clearance for the MicroThermX® Microwave Ablation System. She also serves on the Board of Directors of the Intermountain Biomedical Association.
J. Richard Faux (Director of Operations) joined the company in 1981 and leads BSD’s FDA compliant and ISO-9000 certified manufacturing facility.
Dennis Bradley (Accountant / Secretary) joined BSD in 1985 and has managed the company’s financial records and SEC relations and filings since 1987.
Brian L. Ferrand (VP of Sales) Joined BSD in 2005 as Vice President of Sales. Previously Mr. Ferrand served as Vice President of Sales and as a corporate officer of Merit Medical Systems, Inc. (a company traded on NASDAQ) from 1993 until October 2004. Previously Mr. Ferrand served as Director of Sales from 1992 to 1993 and as a National Sales Manager from 1991-1992 for Merit Medical. Merit Medical Systems is a producer of medical products used in cardiology and radiology sold on a worldwide basis.
Richard A. White, MBA, (VP of Business Development) has been deeply involved in business development and growth since obtaining his degree in international business at The Garvin School of International Management "Thunderbird" in 1980. He has played a key role in the founding of new companies, has led a national sales organization selling large capital equipment in power control systems. He has served as International Sales Manager for Merit Medical Systems, a leading manufacturer and marketer of products used in diagnostic and interventional cardiology and radiology procedures.
Dr. Mark Hagmann (Senior Engineer) joined BSD in 2000. He holds an undergraduate degree in physics and a PhD in electrical engineering. He has occupied important posts in universities and as a Senior Staff Fellow for the National Institutes of Health. Having published well over 100 articles in peer-reviewed journals, his expertise includes hyperthermia, lasers, microwave sciences and biotechnology.
|
|
![]() |
 |
Wm. V.
Frankel & Co., Inc.
30 Montgomery Street
Jersey City, NJ 07302
Tel: (800) 631-3091
Fax: (201) 434-4877 |
Hill Thompson
Magid & Company
15 Exchange Place, Suite 800
Jersey City, NJ 07302
Tel: (800) 450-2566
Fax: (561) 477-3499 |
Herzog,
Heine, Geduld, Inc.
525 Washington Boulevard
Jersey City, NJ 07310-1690
Tel: 800.756.1811
Fax:: 201.418.5006
www.herzog.com |
M. H.. Meyerson &
Co.
525 Washington Blvd.
Jersey City, NJ 07310
Tel: (800) 888-
Fax: (201) 459-0431
www.mhmeyerson.com |
Paragon Capital Corporation
7 Hanover Square, 2nd Floor
New York, NY 10004
Tel: (800) 521-887
Fax: (561) 394-4580 |
Sharpe Capital Incorporated
120 Broadway
New York, NY 10271
Tel: (800) 355-5781
Fax: (212) 267-4217 |
Wilson-Davis
& Company
39 West Market
Salt Lake City, UT 84101
Tel: (800) 453-5735
Fax: (801) 578-2823 |
Wien Securities Corporation
5550 Glades Road, Suite 304
Boca Raton, FL 33431
Tel: (800) 898-2777
Fax: (561) 361-0780 |
Knight Equity Markets, L.P.
545 Washington Blvd.
Jersey City, New Jersey 07310
Telephone: 212.336.8690
Fax: 201.557.6853
Toll Free: 800.544.7508 |
Archipelago Trading Services, Inc.
2300 Maitland Center Parkway
Suite 317
Maitland, FL 32751
407-599-9900
www.archipelago.com |
Citigroup Global Markets, Inc.
388 Greenwich St
New York, NY 10013
Phone: 212-816-6000
Fax: 212-793-9086 |
UBS Capital Markets, L.P.
111 Pavonia Ave. East
Jersey City, NJ 07310
Phone: 201-963-9100
Fax: 201-656-2411
Toll Free: 800-543-7995 |
Fulcrum Global Partners, LLC
New York (Headquarters)
535 Madison Avenue
New York, NY 10022
(212) 803-9000
Toll Free (866) 803-9001 |
|
|
|
|
![]() |
 |
BSD Medical Corporation
(“BSD”) is committed to the highest
standards of legal and ethical business conduct.
This Code of Business Conduct and Ethics summarizes
the legal, ethical and regulatory standards that
BSD Medical Corporation must follow and is a reminder
to our directors, officers and employees, of the
seriousness of that commitment. Compliance with
this Code and high standards of business conduct
is mandatory for every BSD employee.
Introduction
This Code is not intended
to be a comprehensive guide to all of our policies
or to all your responsibilities under law or regulation.
It provides general parameters to help you resolve
the ethical and legal issues you encounter in
conducting our business. Think of this Code as
a guideline, or a minimum requirement, that must
always be followed. If you have any questions
about anything in the Code or appropriate actions
in light of the Code, you may contact the Ethics
Officer, Ray Lauritzen, or the Chair of the Audit
Committee who is Dr. Gerhard Sennewald.
We expect each of our directors,
officers and employees to read and become familiar
with the ethical standards described in this Code
and to affirm your agreement to adhere to these
standards by signing the Compliance Certificate
that appears at the end of this Code. Violations
of the law, our corporate policies, or this Code
may lead to disciplinary action, including dismissal.
I. We Insist on Honest
and Ethical Conduct By All of Our Directors, Officers,
Employees and Other Representatives
We place the highest
value on the integrity of our directors, our officers
and our employees and demand this level of integrity
in all our dealings. We insist on not only ethical
dealings with others, but on the ethical handling
of actual or apparent conflicts of interest between
personal and professional relationships.
Fair Dealing
Directors, officers and employees
are required to deal honestly and fairly with
our customers, suppliers, competitors and other
third parties. In our dealings with customers
and suppliers, we:
- prohibit our directors,
officers and employees from accepting any bribe,
kickback or improper payment from anyone;
- prohibit gifts or favors of
more than nominal value to or from our customers
or suppliers;
- limit marketing and client
entertainment expenditures to those that are
necessary, prudent, job-related and consistent
with our policies;
- require clear and precise communication
in our contracts, our advertising, our literature,
and our other public statements and seek to
eliminate misstatement of fact or misleading
impressions;
- protect all proprietary data
our customers or suppliers provide to us as
reflected in our agreements with them;
Conflicts of Interest; Corporate
Opportunities
Our directors, officers and
employees should not be involved in any activity
that creates or gives the appearance of a conflict
of interest between their personal interests and
the interests of BSD. In particular, without the
specific permission of our Ethics Officer, no
director, officer or employee shall:
- be a consultant to, or
a director, officer or employee of, or otherwise
operate an outside business that:
- markets products or services
in competition with our current or potential
products and services;
- supplies products or services
to BSD; or
- purchases products or services
from BSD;
- have any financial interest,
including significant stock ownership, in any
entity with which we do business that might
create or give the appearance of a conflict
of interest;
- seek or accept any personal
loan or services from any entity with which
we do business, except from financial institutions
or service providers offering similar loans
or services to third parties under similar terms
in the ordinary course of their respective businesses;
- accept any personal loan or
guarantee of obligations from BSD, except to
the extent such arrangements are legally permissible;
or
- conduct business on behalf
of BSD with immediate family members, which
include spouses, children, parents, siblings
and persons sharing the same home whether or
not legal relatives.
Confidentiality and Corporate
Assets
Our directors, officers and
employees are entrusted with our confidential
information and with the confidential information
of our suppliers, customers or other business
partners. This information may include (1) technical
or scientific information about current and future
products, services or research, (2) business or
marketing plans or projections, (3) earnings and
other internal financial data, (4) personnel information,
(5) supply and customer lists and (6) other non-public
information that, if disclosed, might be of use
to our competitors, or harmful to our suppliers,
customers or other business partners. This information
is our property, or the property of our suppliers,
customers or business partners and in many cases
was developed at great expense. Our directors,
officers and employees shall:
- Not discuss confidential
information with or in the presence of any unauthorized
persons, including family members and friends;
- Use confidential information
only for our legitimate business purposes and
not for personal gain;
- Not disclose confidential information
to third parties.
II. We Provide Full, Fair,
Accurate, Timely and Understandable Disclosure
We are committed to providing
our shareholders and investors with full, fair,
accurate, timely and understandable disclosure
in the reports that we file with the Securities
and Exchange Commission. To this end, our directors,
officers and employees shall:
- not make false or misleading
entries in our books and records for any reason;
- not condone any undisclosed
or unrecorded bank accounts or assets established
for any purpose;
- comply with generally accepted
accounting principles at all times;
- notify our Accountant if there
is an unreported transaction;
- maintain a system of internal
accounting controls that will provide reasonable
assurances to management that all transactions
are properly recorded;
- maintain books and records
that accurately and fairly reflect our transactions;
- prohibit the establishment
of any undisclosed or unrecorded funds or assets;
- maintain a system of internal
controls that will provide reasonable assurances
to our management that material information
about BSD is made known to management, particularly
during the periods in which our periodic reports
are being prepared;
- present information in a clear
and orderly manner and avoid the use of unnecessary
legal and financial language in our periodic
reports; and
III. We Comply With all
Laws, Rules and Regulations
We will comply with
all laws and governmental regulations that are
applicable to our activities, and expect all our
directors, officers and employees to obey the
law. Specifically, we are committed to:
- maintaining a safe and
healthy work environment;
- promoting a workplace that
is free from discrimination or harassment based
on race, color, religion, sex, age, national
origin, disability or other factors that are
unrelated to the Company’s business interests;
- supporting fair competition
and laws prohibiting restraints of trade and
other unfair trade practices;
- conducting our activities in
full compliance with all applicable environmental
laws;
- keeping the political activities
of our directors, officers and employees separate
from our business;
- prohibiting any illegal payments,
gifts, or gratuities to any government officials
or political party;
- prohibiting the unauthorized
use, reproduction, or distribution of any third
party’s trade secrets, copyrighted information
or confidential information;
- complying with all applicable
state and federal securities laws.
REPORTING AND EFFECT
OF VIOLATIONS
Compliance with this
code of conduct is, first and foremost, the individual
responsibility of every director, officer and
employee. We attempt to foster a work environment
in which ethical issues and concerns may be raised
and discussed with supervisors or with others
without the fear of retribution. It is our responsibility
to provide a system of reporting and access when
you wish to report a suspected violation, or to
seek counseling, and the normal chain of command
cannot, for whatever reason, be used.
Administration
Our Board of Directors and
Audit Committee have established the standards
of business conduct contained in this Code and
oversees compliance with this Code. They have
also created the position of Ethics Officer to
ensure adherence to the Code. While serving in
this capacity, the Ethics Officer reports directly
to the Board of Directors.
Reporting Violations and Questions
Directors, officers, and employees
must report, in person or in writing, any known
or suspected violations of laws, governmental
regulations or this Code to either the Ethics
Officer or the Chair of the Audit Committee of
our Board of Directors. Additionally, directors,
officers, and employees may contact the Ethics
Officer or the Chair of the Audit Committee with
a question or concern about this Code or a business
practice. Any questions or violation reports will
be addressed immediately and seriously, and can
be made anonymously.
We will not allow any retaliation
against a director, officer or employee who acts
in good faith in reporting any violation.
Our Ethics Officer will investigate
any reported violations and will determine an
appropriate response, including corrective action
and preventative measures, involving the Chair
of the Audit Committee or Chief Executive Officer
when required. All reports will be treated confidentially
to every extent possible.
Consequences of a Violation
Directors, officers and employees
who violate any laws, governmental regulations
or this Code will face appropriate, case specific
disciplinary action, which may include demotion
or immediate discharge.
|
|
![]() |
 |
One committee of the board of directors will be known as the audit committee,
comprising at least two members. A majority of the members of the audit committee shall be independent
directors.
The primary function of the audit committee is to assist the board in fulfilling its oversight
responsibilities by reviewing the financial information that will be provided to the shareholders
and others, the systems of internal controls management and the board of directors have established
and all audit processes.
General responsibilities
- The audit committee provides open avenues of communication with the independent accountant and the board of directors.
- The audit committee must report committee actions to the full board of directors and may make appropriate recommendations.
- The audit committee has the power to conduct or authorize investigations into matters within the committee's scope of responsibilities. The committee is authorized to retain independent counsel, accountants or others it needs to assist in an investigation.
- The audit committee will meet at least one time each year, more frequently if circumstances make that preferable. The audit committee chairman has the power to call an audit committee meeting whenever he or she thinks there is a need.
An audit committee member should not vote on any matter in which he or she is not independent. The audit committee may ask members of management or others to attend the meeting and is authorized to receive all pertinent information from management.
- The audit committee will do whatever else the law, the company's charter or bylaws or the board of directors require.
Responsibilities for engaging independent accountants and appointing the internal auditor
- The audit committee will select the independent accountants for company audits. The committee's selection is subject to approval by the full board of directors. The audit committee also will review and set any fees paid to the independent accountants and review and approve dismissal of the independent accountants.
- The audit committee will confirm and assure the independence of the independent accountant, including a review of consulting services provided by the independent accountant and the fees paid for them.
- The audit committee will consider, in consultation with the independent accountant the audit scope and procedural plans made by the independent accountant.
- The audit committee will listen to management and the primary independent auditor if either thinks there might be a need to engage additional auditors. The audit committee will decide whether to engage an additional firm and, if so, which one.
Responsibilities for reviewing internal audits, the annual external audit and the review of quarterly and annual financial statements
- The audit committee will ascertain that the independent accountant views the board of directors as its client, that it will be available to the full board of directors at least annually and that it will provide the committee with a timely analysis of significant financial reporting issues.
- The audit committee will ask management and the independent accountant about significant risks and exposures and will assess management's steps to minimize them.
- The audit committee will review the following with the independent account:
- The adequacy of the company's internal controls, including computerized information system controls and security.
- Any significant findings and recommendations made by the independent accountant, together with management's responses to them.
- Shortly after the annual examination is completed, the audit committee will review the following with management and the independent accountant:
- The company's annual financial statements and related footnotes.
- The independent accountant's audit of and report on the financial statements.
- The auditor's qualitative judgments about the appropriateness, not just the acceptability, of accounting principles and financial disclosures and how aggressive (or conservative) the accounting principles and underlying estimates are.
- Any serious difficulties or disputes with management encountered during the course of the audit.
- Anything else about the audit procedures or findings that GAAS requires the auditors to discuss with the committee.
- The audit committee will review annual filings with the SEC and other published documents containing the company's financial statements and will consider whether the information in the filings is consistent with the information in the financial statements.
- The audit committee will review the interim financial reports with management and the independent accountant before those interim reports are released to the public or filed with the SEC or other regulators.
- The audit committee will prepare a letter for inclusion in the annual report that describes the committee's composition and responsibilities and how the responsibilities were fulfilled.
Periodic responsibilities
- Review and update the audit committee's charter annually.
- Review, with the independent accountant, the results of their examination of compliance with the company's code of conduct.
- Review legal and regulatory matters that may have a material effect on the organization's financial statements, compliance policies and programs and reports from regulators.
- Meet with the independent accountant and management in separate executive sessions to discuss any matters the audit committee or these groups believe should be discussed privately with the audit committee.
|
|
|
 |
Certain statements
in the web site that relate to the future performance
of BSD Medical Corporation or therapies performed
on our equipment are "forward-looking"
and are subject to risks and uncertainties inherent
in our business that could cause actual results
to differ materially from the statements. BSD
Medical Corp. does not undertake responsibility
to update such forward-looking statements. A detailed
discussion of risks and uncertainties may be found
in our Annual Report on Form 10-K and other documents
filed with the Securities and Exchange Commission.
Our recent SEC filings are available from this
web site. BSD Medical Corporation is not responsible
for nor do we endorse claims made on links included
on our website.
|
|
![]() |
|
|
| |
|